| Note
Organizational Changes:
Dr. Steven Galson, M.D., is
acting CDER director.
The
Office of Post-Marketing Drug
Risk Assessment (OPDRA) has
been renamed the Office of
Drug Safety (ODS) and the
Office Director is Paul Seligman
M.D.
Also, the division within
CDER's Office of Compliance
responsible for all post-marketing
surveillance activities has
been renamed the Division
of Compliance Risk Management
and Surveillance and the Acting
Director is Kathy Miracco.
Current CDER Organization
Chart |
.gif){kind=small}
.gif){kind=spacer}
